Roberts Glore & Co. Inc. IL Buys 7,946 Shares of Novo Nordisk A/S (NYSE:NVO)

Key Points

• Roberts Glore & Co. Inc. increased its holdings in Novo Nordisk A/S by 252.8% during the first quarter, owning 11,089 shares worth approximately $770,000.
• Several large investors also raised their stakes in Novo Nordisk, with North Star Investment Management Corp. and Bank of New York Mellon Corp. increasing their positions by 18.2% and 6.0%, respectively.
• Novo Nordisk A/S reported $0.92 earnings per share for the last quarter, meeting analyst estimates, and has a current average price target of $93.67 from equity research analysts.

Roberts Glore & Co. Inc. IL lifted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 252.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,089 shares of the company's stock after acquiring an additional 7,946 shares during the quarter. Roberts Glore & Co. Inc. IL's holdings in Novo Nordisk A/S were worth $770,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Nuveen Asset Management LLC lifted its holdings in shares of Novo Nordisk A/S by 73.2% during the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock worth $537,189,000 after purchasing an additional 2,639,693 shares during the period. Two Sigma Investments LP acquired a new position in Novo Nordisk A/S during the 4th quarter worth about $158,657,000. Bank of America Corp DE lifted its holdings in Novo Nordisk A/S by 8.1% during the 4th quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock worth $1,332,655,000 after buying an additional 1,165,955 shares during the period. Northern Trust Corp grew its position in shares of Novo Nordisk A/S by 26.8% in the 4th quarter. Northern Trust Corp now owns 4,689,098 shares of the company's stock valued at $403,356,000 after buying an additional 991,022 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Novo Nordisk A/S by 543.9% in the fourth quarter. Marshall Wace LLP now owns 1,167,498 shares of the company's stock valued at $100,428,000 after buying an additional 986,195 shares during the period. Institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on NVO shares. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. HSBC downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price for the company. in a research note on Thursday, July 31st. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Hsbc Global Res lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $93.67.

Novo Nordisk A/S Stock Down 4.0%

Shares of NVO stock traded down $1.91 on Wednesday, reaching $45.31. 37,329,473 shares of the company were exchanged, compared to its average volume of 20,605,628. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The company has a 50-day moving average of $68.43 and a 200-day moving average of $72.20. The company has a market cap of $202.31 billion, a price-to-earnings ratio of 13.41, a PEG ratio of 1.43 and a beta of 0.63. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.08. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.